Bivalirudin

Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others[1][2][3][4].

Product Specifications

CAS Number

[128270-60-0]

UNSPSC

12352209

Hazard Statement

H302, H312, H332

Target

Interleukin Related; RSV; Thrombin

Type

Peptides

Related Pathways

Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Infection; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/bivalirudin.html

Purity

99.97

Solubility

H2O : 10 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(CCC1)C([C@H](CCCNC(N)=N)NC([C@H]2N(CCC2)C([C@H](N)CC3=CC=CC=C3)=O)=O)=O)NCC(NCC(NCC(NCC(N[C@@H](CC(N)=O)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N5[C@@H](CCC5)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(O)=O)CC(C)C)=O)CC6=CC=C(C=C6)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C98H138N24O33

Molecular Weight

2180.29

Precautions

H302, H312, H332

References & Citations

[1]André P, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.Circulation. 2003 Nov 25;108 (21) :2697-703.|[2]Ye H, et al. Bivalirudin Attenuates Thrombin-Induced Endothelial Hyperpermeability via S1P/S1PR2 Category: Original Articles. Front Pharmacol. 2021 Aug 3;12:721200.|[3]Zhuang S, et al. Bivalirudin exerts antiviral activity against respiratory syncytial virus-induced lung infections in neonatal mice. Acta Pharm. 2022 Apr 13;72 (3) :415-425.|[4]Warkentin TE, et al. Bivalirudin: a review. Expert Opin Pharmacother. 2005 Jul;6 (8) :1349-71.